AEON Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

AEON Biopharma Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerAEON

Market Cap19.6M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

AEON Biopharma Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for ABP-450 in Migraine (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
ABP-450	Migraine	n/a	Phase 2	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT04849988	Phase 2	COMPLETED	61	2022-07-11
NCT04871451	Phase 2	COMPLETED	51	2023-07-24
NCT04845178	Phase 2	COMPLETED	797	2024-06-19
NCT05016661	Phase 2	TERMINATED	466	2024-07-31

Scientific Context

literature_publication | Lotilaner ophthalmic solution 0.25% in the treatment of Demodex blepharitis: A case report.
literature_publication | International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine.
literature_publication | Efficacy and Safety of Eptinezumab in Episodic Cluster Headache: A Randomized Clinical Trial.
literature_publication | The Demodex Expert Panel on Treatment and Eyelid Health (DEPTH) Consensus Regarding the Preferred Treatment for Demodex Blepharitis.
literature_publication | Amylin and the amylin receptors in migraine: Is there another pathway to target?

Want the full AEON research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.